International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 31, Issue 5, May 2025 ijppr.humanjournals.com ISSN: 2349-7203

A Comparative Review of Atopic Dermatitis and Contact Dermatitis: Pathophysiology, Clinical Insights, Therapeutic Approaches, and Future Directions

Archana P [1*], Dr. Sabbathyan Balla [2], Dr. P. Amudha [3].

[1*] Department of Pharmacology, C.L. Baid Metha College of Pharmacy, Rajiv Gandhi Salai, Old Mahabalipuram Road, Jyothinagar, Thorappaikam, Chennai -600097, Tamil Nadu, India.
[2]Assistant Professor, Department of Pharmacology, C.L. Baid Metha College of Pharmacy, Rajiv Gandhi Salai, Old Mahabalipuram Road, Jyothinagar, Thorappaikam, Chennai -600097, Tamil Nadu, India.
[3]Professor,& HOD Department of Pharmacology, C.L. Baid Metha College of Pharmacy, Rajiv Gandhi Salai, Old Mahabalipuram Road, Jyothinagar, Thorappaikam, Chennai - 600097, Tamil Nadu, India.

Received: 2025-04-25 Revised: 2025-05-05 Accepted: 2025-05-10

ABSTRACT:

Atopic dermatitis (AD) & Contact dermatitis are dermatological disorders that significantly impact skin barrier function and quality of life. AD, a chronic genetic condition, affects around 204 million people worldwide, with higher rates in children and a female predominance. CD, characterized by delayed-type hypersensitivity to environmental haptens, affects about 20% of the general population as contact allergy. The prevalence of occupational CD exhibits significant variability, with register-based investigations indicating a range of 0.6 to 6.7 occurrences per 10,000 person-years. In contrast, cohort studies imply elevated rates, especially among high-risk occupations such as healthcare professionals, beauticians, and machinists. Underreporting remains a critical issue, with self-reported work-related CD prevalence doubling clinician-attributed estimates. Emerging therapies include biologics, herbal interventions, and barrier repair strategies. Healthcare workers must prioritize early diagnosis, allergen avoidance, and tailored management to mitigate occupational risks, especially in industrialized settings where CD accounts for up to 90% of occupational dermatoses.

Keywords: Contact Dermatitis, Atopic Dermatitis, Immune Dysregulation, & Diagnosis

1. INTRODUCTION

Skin is a multi-layered organ that serves as the body's main defences against mechanical forces, microbes, and water loss. It also regulates temperature, synthesizes vitamin D, contains sensory functions. Skin structure consists of three main layers: epidermis, dermis, & hypodermis[1]. Atopic and contact dermatitis are the two most prevalent forms of dermatitis, which is an inflammation of the skin. Both conditions present symptoms such as redness, itching, & scaling[2-4].

1.1 Description of Dermatitis

Dermatitis is the inflammation of the skin, with atopic dermatitis & contact dermatitis being the two most common types. Both conditions present with symptoms such as redness (entails erythema), itching (pruritus), & scaling. Still, they differ greatly in their causes, pathogenesis, & operation. Grasping these distinctions is critical for acclimatized remedial strategies.

1.2 Types of Dermatitis

1. Atopic Dermatitis: Chronic inflammatory skin disease with genetic pre-disposition [5].

2. Contact Dermatitis: Caused by direct contact with irritants or allergens [6].

3. Seborrheic Dermatitis: Affects areas rich in sebaceous glands like the scalp, &face [7].

4. Nummular Dermatitis: Coin-shaped lesions, mainly on the limbs [8].

5. Neurodermatitis (Lichen Simplex Chronicus): Caused by chronic scratching & rubbing [8].

6. Perioral Dermatitis: Papular rash around the mouth and eyes [9].

7. Stasis Dermatitis: Associated with chronic venous insufficiency, 1˚ in the lower legs [10].

8. Dyshidrotic Dermatitis: It is also known as dyshidrotic eczema or pompholyx. It is a skin condition causing small, itchy blisters on the hands or feet. It leads to redness, inflammation, dryness, & cracked skin[11-14].

1.3 Atopic Dermatitis Definition

Atopic dermatitis (AD) is a chronic, relapsing form of inflammatory skin disease characterized by pruritus, xerosis, and eczematous lesions[11-15]. It is mainly driven by a Th2-polarized immune response & is primarily caused by genetic mutations like the deficiency of filaggrin, which weakens the skin barrier & increases Th2 immune responses [12,13].

E.g.: Lichenified (Antecubital) Thickened, leathery skin with hyperpigmentation (darker skin) or redness (lighter skin). Accentuated skin creases.

1.4 Contact Dermatitis Definition

It is also known as contact hypersensitivity, the inflammation of skin due to contact with immune or non-immune factors, as in ICD, which prompts the AD7. [Or] A localized inflammatory skin reaction called contact dermatitis (CD) develops when the skin comes into direct contact with an outside cause, including an irritant or an allergy[14,15].

Clinically, CD is characterized by symptoms and signs that include redness (erythema), swelling (edema), blisters (vesiculation), itching (pruritus), and scaling of the skin and these are localized to the area of exposure [16-18].

E.g: ACD (e.g., Nickel)Red/pink (lighter skin) or purple/gray (darker skin) patches with vesicles (small blisters) and oozing. Distinct borders that correspond to allergen interaction (such as the shape of a belt buckle).

1.5 Skin Layers Impacted in Atopic & Contact Dermatitis

Skin disorders like contact dermatitis (CD) and atopic dermatitis (AD) affect these layers differently[18]. Contact dermatitis engages the epidermis and upper dermis, where there exists inflammation. Atopic dermatitis is also characterized by epidermal barrier disruption and chronic inflammation in the dermis. Understanding these distinctions is critical for tailored therapeutic strategies [19,20].

2. CLASSIFICATION AND TYPES OF ATOPIC DERMATITIS(AD) & CONTACT DERMATITIS(CD)

2.1 Comparison of AD & CD Classification

The comparison of AD & CD classification **(Table 1)** is based on primary basis, subtypes and clinical course.

Table 1. Below Shows a Comparison AD & CD Classification:

Feature	Atopic Dermatitis	Contact Dermatitis	References numbers
Primary Basis	Exposure-based: Allergens/irritants (external factors).	Endogenous: Genetic predisposition (filaggrin mutations) + immune dysregulation.	[20,22]
Subtypes	1. Allergic Contact Dermatitis (Type IV hypersensitivity). 2. Irritant Contact Dermatitis (direct cytotoxicity). 3. Photoinduced (phototoxic/photoallergic). 4. Systemic Contact Dermatitis.	1. Extrinsic (IgE-high phenotype). 2. Intrinsic (IgE-normal phenotype). 3. Regional variants (Asian/European phenotypes).	[23-27]

Clinical Course	⁎Acute: Rapid onset (hours),& monomorphic lesions. ⁎Chronic: Hyperkeratotic, fissured skin (months-years).	⁎Infantile: Cheek/extensor involvement. ⁎Childhood: Flexural lichenification. ⁎Adult: Hand/ocular dominance.	[28-33]

2.2 Types of Atopic Dermatitis

1. Extrinsic: IgE-High phenotype, Filaggrin mutations,& food/environmental triggers. Subtypes: Early-onset, food-associated, late-onset, Suprabasin-deficient[28].

2. Intrinsic**:** Female predominance, metal allergy connection, and IgE-normal phenotype. Subtypes: Late-onset, Suprabasin-deficient[29,32].

3. Regional Variants: Geographic Variation. Subtypes: European, African,& American.

4. Clinical Patterns: Morphology classification. Subtypes: Nummular, Prurigo,& Erythrodermic[30-33].

5. Phenotypes: Age-related symptoms. Subtypes: Infantile, Childhood, &Adult[34].

2.3 Types of Contact Dermatitis

1. Allergic Contact Dermatitis: Type IV hypersensitivity, requiring sensitization prerequisites like nickel, fragrances. Subtypes include IgE Protein &Transfer contact dermatitis[35,36].

2. Irritant Contact Dermatitis: Detergents, acids, dryness, fissures, hyperkeratosis. Subtypes include chemical becks, habitual low-grade irritant exposure, & trauma-induced dermatitis[37].

3. Photo Contact Dermatitis: Response to UV radiation. Subtypes include phototoxic reaction & photoallergenic[38].

4. Systemic Contact Dermatitis: Dermatitis arising from exposure to obat, with Subtypes including baboon rash & SDRIFE[39].

5. Contact Urticaria: Immunological skin reaction with IgE-mediated hypersensitivity to latex.

6. Non-Eczematous Dermatitis: Dermatosis resembling other types. Subtypes include lichen planus-like, violaceous.

7. Special Forms: Location-specific.Subtypes include occupational hand dermatitis [26-30].

3. AETIOLOGY COMPARISON: CONTACT DERMATITIS AND ATOPIC DERMATITIS

Both conditions have unique factors influencing their severity. Atopic dermatitis is influenced by genetic inheritance, immunity, initial appearance, & controllable factors. It's often due to type HypersensitivityI allergic reaction mediated by IgE. It's linked to certain genes, disability skin barrier type, and some active agents. Flare-ups of allergic dermatitis are not active and are common in young children or individuals with family allergies. Contact dermatitis results from internal stimuli/external exposures. Sub-categories include CID (non-immunity, result chemical or mechanical destruction, allergy contact dermatitis), ACD (IV type allergic reaction), & Detergent type ACD (blocks of acids & other irritants as triggers) [30-34].

4. COMPARISON OF PATHOPHYSIOLOGIC STUDIES IN ATOPIC DERMATITIS & CONTACT DERMATITIS

The comparison of pathophysiologic studies in atopic & contact dermatitis **(Table 2).** The study compares atopic and contact dermatitis, revealing that atopic dermatitis is caused by genetic defects, decreased ceramides, and increased inflammation, while contact dermatitis disrupts the skin barrier after repeated exposure, resulting in chemical injury or allergic response.

Table 2. Below Shows a Comparison of Pathophysiologic Studies In Atopic Dermatitis & Contact Dermatitis:

Aspects	Atopic Dermatitis	Contact Dermatitis	Reference Numbers
Skin Barrier Function	Inherent Defect due to filaggrin gene mutation, ↓ ceramides, & ↑transepidermal water loss.	⁎Usually normal before exposure. ⁎Disrupted after repeated irritation or allergen exposure.	[25]
Trigger Mechanism	Begins with barrier breakdown, allowing allergen penetration →immune dysregulation → chronic inflammation.	⁎Irritant CD: Direct chemical injury to keratinocytes. ⁎Allergic CD: T-cell response specific to allergens.	[29-32]
Immune System Involvement	Primarily Type 1 hypersensitivity dominant Th2 immune response in acute phase (IL-4,IL-5,& IL-13).	⁎Irritant CD: Activation of keratinocytes causes non-immune inflammation ⁎Allergic CD: Type IV hypersensitivity (T-cell mediated, delayed).	[30]
Cell Types Involved	Langerhans cells, Th2 cells, eosinophils, Mast cells, Basophils & keratinocytes.	⁎Irritant CD: Keratinocytes, &neutrophils. ⁎ Allergic CD: Langerhans cells,& T-helper cells.	[31,32]
Cytokines	⁎Acute: ↑IL-4,IL-5, &IL-13 (Th2). ⁎Chronic: ↑IFN-γ (Th1), & IL-17,IL-22 (Th17/Th22 Pathways).	Allergic CD: ↑ IFN-Y, IL-17, &TNF-α.	[33]
Chronicity & Progression	⁎Chronic & relapsing, even without visible triggers. Inflammation becomes mixed (Th2+Th17)	⁎Often resolves with the removal of the trigger. ⁎Chronic with ongoing exposure.	[34,35]

5. HERBAL MANAGEMENT OF ATOPIC VS. CONTACT DERMATITIS

Herbal treatments for contact dermatitis include anti-inflammatory, antimicrobial, & barrier-repairing agents. Common treatments include aloe vera gel, chamomile compresses, oatmeal bath, and calendula. Thyme infusions are used for infected lesions due to their antiseptic properties. Mallow decoctions soften the skin due to mucilage. Herbal treatments for atopic dermatitis induce long-term immune modulation and repair of the epidermal barrier. Neem, turmeric, liquorice root, coconut oil, St. John's wort, and gotu kola are among the top choices.Evening primrose oil has inconclusive results against a placebo. Combined aloe vera-olive oil treatment is superior for relieving itching. Chinese/Korean herbs like Indigo Naturalis reduce SCORAD scores by inhibiting IL-31[64]. CD treatments target passing symptoms, while AD treatments target chronic immunologic issues. Both conditions are treated with colloidal oatmeal baths, while AD may require stress-reducing adaptogens like ashwagandha[27-29].

6. *IN - VITRO* CD & AD MODELS

In -Vitro CD tests use 3D epidermal equivalents exposed to nickel or irritants to quantify Langerhans cell activation and barrier disruption. Keratinocyte monocultures exposed to haptens show NLRP3 inflammasome activation, IL-1β release, oxidative stress, elevated CXCL8/IL-8, and reduced occludin. Mast cell-keratinocyte cocultures (HMC-1/HaCaT) simulate urushiol-induced CD through TRPV1-dependent IL-6/IL-8 release, whereas Langerhans cell-T-cell cocultures illustrate hapten-specific CD8+ T-cell proliferation and IFN-γ dominance.AD models utilize filaggrin-deficient HaCaT cells (CRISPR-edited) and reconstructed human epidermis (RHE) from AD patient skin to mimic Th2 cytokines (IL-4, IL-13, IL-22) for drug screening. Immune cell cocultures and 3D skin equivalents (Langerhans cells + T-cells with IL-4/IL-13) control Th2 polarization and barrier repair[28].

7. CLINICAL MANIFESTATIONS OF ATOPIC DERMATITIS VS. CONTACT DERMATITIS

The Clinical Manifestations of Atopic dermatitis vs. Contact Dermatitis **(Table 3)** highlights that Atopic dermatitis is characterized by intense itching & erythematous papules or vesicles, which may ooze & progress to lichenification pigmentation changes. In contrast, contact dermatitis is marked by itching or burning, sometimes with pain in severe cases. The distribution of lesions depends on age and exposure sites for atopic dermatitis and contact dermatitis. Both conditions require advanced treatment & histopathology.

Table 3. Below Shows the Clinical Manifestations of Atopic Dermatitis Vs. Contact Dermatitis:

Aspects	Atopic Dermatitis	Contact Dermatitis	Reference Numbers
Primary Symptom	Intense pruritus ("itch that rashes"), often nocturnal.	Itching/burning, with pain in severe irritant CD.	[28]
Skin Lesions	⁎Acute: Erythematous papules/vesicles with oozing. ⁎Chronic: Lichenification, excoriations, & hyper/hypopigmentation.	⁎ACD: Vesicles, erythema, & scaling. ⁎ICD: Dry fissures, hyperkeratosis.	[29,30]
Distribution	Age-dependent: ⁎Infants: Cheeks/extensors. ⁎Children: Flexural. ⁎Adults: Hands/eyelids.	Exposure-dependent: ⁎Allergic: Geometric patterns (e.g., watchband rash). ⁎ Irritant: Dorsal hands.	[30]
Skin Changes	⁎Xerosis (universal), Dennie-Morgan folds (double infraorbital creases). ⁎Keratosis pilaris (arm bumps).	⁎ACD: Delayed hypersensitivity reaction (48-72h post-exposure). ⁎ICD: Immediate stinging/erythema.	[31]
Complications	⁎Secondary infections (*S. aureus*, HSV) Erythroderma (>90% body involvement). ⁎Ocular: Cataracts, & keratoconus.	⁎Infected ACD (rare). ⁎Chronic ICD: Lichenification.	[33]
Ethnic Variations	⁎Darker skin: Papular lesions,& dyspigmentation. ⁎Asian AD: Follicular accentuation.	⁎Darker skin: Violaceous hues. ⁎Occupational CD: Higher in healthcare/construction workers.	[30-34]
Diagnostic Clues	⁎Hanifin-Rajka criteriaElevated IgE (extrinsic subtype). ⁎Filaggrin mutations (FLG).	⁎Patching testing (ACD Confirmation). ⁎Exposure history (ICD).	[31-39]
First-line	⁎Emollients (multiple daily applications). ⁎Low-mid potency TCS (e.g. hydrocortisone 2.5%).	⁎Allergen avoidance (definitive treatment). ⁎Topical corticosteroids (medium potency for 2-3 weeks).	[32]
Severe cases	⁎Systemic agents: Cyclosporine, & dupilumab. ⁎Hospitalization for erythroderma.	⁎Prednisone 0.5-1 mg/kg/day (7-14 days). ⁎Phototherapy (PUVA/NB-UVB for chronic cases).	[33]
Adjunct Therapies	⁎Wet wrap therapy (with diluted steroids). ⁎Bleach baths (0.005% sodium hypochlorite).	⁎Barrier creams (dimethicone/zinc oxide). ⁎Antihistamines (sedating types for nocturnal itch).	[34]
Emerging Therapies	JAK inhibitor (abrocitinib approved) IL-31RA antagonists (nemolizumab).	JAK inhibitors (limited evidence). IL-4/13 antagonists (no trials).	[34,35]
Histopathology	⁎Acute: Spongiosis, CD4+ T-cell infiltrate. ⁎Chronic: Hyperkeratosis, & Lichenification.	⁎ACD: Epidermal spongiosis, CD8+ T-cells. ⁎ICD: Necrotic keratinocytes.	[35-37]
Quality of Life Impact	⁎Severe: Sleep loss, & work impairment. ⁎Mental health: Anxiety/depression.	Occupational disability (Hand CD). Social stigma(Visible facial lesions).	[36-38]

8. DRUGS, PHARMACOLOGY ACTION, CLINICAL GUIDELINES, ADVERSE EFFECTS, & USES IN ATOPIC & CONTACT DERMATITIS

8.1 (Topical Corticosteroids) Drugs Classification & Action

• TCS: Clobetasol, Triamcinolone,& Hydrocortisone[36].

• Biologics: Dupilumab,& Abrocitinib.

• JAK Inhibitors: Abrocitinib.

• Calcineurin inhibitors: Tacrolimus.

• TCS in chronic dermatitis: Hydrocortisone, Clobetasol, & Mometasone.

• Antihistamines: Diphenhydramine.

• Calcineurin Inhibitors: off-label use not limited.

8.2 Pharmacology & Mechanism of Action

• TCS binds to glucocorticoid receptors.

• Anti-inflammatory: Blocks phospholipase A2.

• T-cell activation and dendritic cell function are immunosuppressive.

• Clinical effects: Anti-pruritic, Anti-inflammatory, Vasoconstrictive, & Anti-proliferative.

Classification of topical corticosteroids. Topical corticosteroids are categorized into six groups, according to potency, tested using the vasoconstrictor assay, which is a measure of the potency of topical corticosteroids:

Class I : Super potent - E.g., Clobetasol propionate 0.05%

Class II : Potent – E.g., Betamethasone dipropionate

Class III: Moderate (High)-potent- E.g., Triamcinolone acetonide 0.1%.

Class IV: Moderate (Mid)-potent- E.g., Mometasone furoate 0.1%.

Class V: Moderate (Low) -potent - E.g., Hydrocortisone valerate 0.2%.

Class VI: Mild – E.g., Hydrocortisone 1%.

Class VII: Least potent- E.g., Hydrocortisone 0.5%.

NOTE: Utilize these depending on the severity &anatomical region of the lesions (i.e., mild steroids for the face/groin area) [37].

8.3 Clinical Guidelines

• Potency: Class VI and VII for face/groin, Class I & II for drug-induced psoriasis/lichenification lesions[38,39].

• Use: Fingertip Unit (FTU): ~0.5g & ~2% body area.

• Frequency: Once daily results in similar efficacy as dosing several times daily.

• Monitoring: Skin atrophy 2-4 weeks, avoid abrupt withdrawal[39,60].

• Special groups: Face/groin risk of atrophy, telangiectasia.

• Clinical uses: TCS for acute flares, Dupliumab for chronic moderate-severe AD, JAK inhibitors for refractory AD. TCS for acute inflammation in CD, antihistamines for pruritus relief.

8.4 Adverse drug effects & uses

•**ADR:** Skin atrophy, stretch mark, Hypo-pigmentation, & etc[38,39].

•**Uses:** Lichen planus, Eczema, Psoriasis, & etc[39].

9. ADMINISTRATION ROUTES AND FORMULATIONS IN ANIMAL MODELS

• Creams: Act as a boundary cream in CD for intense, wet injuries, anticipating irritation.Treatments: For unremitting, dry, thickened lesions

.• Gels: Lightweight, non-comedogenic options for cosmetic acceptance.

• Phototherapy: In AD, Narrowband UVB-↓ Inflammation[40].

• Nano-formulations: Liposomes, ethosomes, & solid lipid nanoparticles way for better skin penetration[41].

• Topical: Treatments Dermatophagoides farinae extract, tacrolimus, nanocarriers (liposomes, ethosomes), Betamethasone valerate.Lotions: Hydrocortisone[42,43].

• Oral: Herbal extracts: Scutellarin, baicalinase, & Glycyrrhiza glabra. Immunosuppressants: Cyclosporine.

• Subcutaneous-In AD biologics: Lokivetmab (canine models).

• Intraperitoneal in anti-IL-4 Anti-IL-4/IL-13 antibodies (experimental murine models)

• Intranasal: Under exploration for immunotherapy in allergic dermatitis.

• Injectable (SC/IV): Biologics like dupilumab for AD [62,63].

10. INDUCTION APPROACHES IN ATOPIC DERMATITIS (AD) VS. CONTACT DERMATITIS (CD)

The Induction Approaches In Atopic Dermatitis (AD) vs. Contact Dermatitis (CD) in **(Table 4)**. As highlighted, the models for atopic dermatitis commonly use NC/Nga mice, Flaky Tail mice, and BALB/c mice, including genetic models with spontaneous barrier defects. In contrast, contact dermatitis models typically use NC/Nga and BALB/c mice but lack a strong genetic basis, relying instead on exposure-based induction in various animal species.

Table 4. Below Shows an Induction Approach in Atopic Dermatitis (AD) Vs. Contact Dermatitis (CD):

Features	Atopic Dermatitis (AD)	Contact Dermatitis (CD)	Reference Numbers
Common animal models	NC/Nga mice, Flaky Tail mice, BALB/c mice, C57BL/6mice, zebra fish, cats, Wistar Rats, dogs, rabbits & guinea pigs.	NC/Nga mice, BALB/c mice, C57BL/6mice,wistar rats, dogs,cats rabbits & guinea pigs.	[44]
Genetic Models	⁎Flaky Tail mice (FLG/Tmem79 mutations) with spontaneous barrier defects. ⁎NC/Nga mice under conventional housing develop IgE-mediated lesions.	Not applicable (CD lacks strong genetic basis for induction).	[46,47]
Allergens Induction Methods	⁎House dust mite (HDM) patches induce Th2 inflammation (IL-4/IL13). ⁎Ovalbumin epi-cutaneous sensitization mimics chronic lichenification. ⁎Others, such as DNCB, DNFB, &oxazolone. ⁎Procedure: Shaved dorsal skin is applied repeatedly by epicutaneous application for 2–8 weeks.	⁎DNCB allergen sensitization, Haptens: DNFB, oxazolone, or nickel applied topically to induce Type IV hypersensitivity. ⁎Irritants:Urushiol analogs (e.g., pentadecylcatechol) trigger TRPV1-dependent itch. Others such as TNFB, SLD, & Picryl anhydride. ⁎Procedure: Multiple applications on the ear or back skin (5-14 days).	[47-49]
Cytokine-Based Models	⁎Th2 cytokine cocktails (IL-4/IL-13 ± IL-31) suppress FLG in 3D skin models. ⁎IL-33/TSLP overexpression in keratinocytes drives pruritus.	⁎IFN-γ/IL-17 dominate hapten-induced inflammation in mice. ⁎IL-1β/IL-18 from keratinocytes activate Langerhans cells in co-cultures.	[50-53]

Microbiome Modulation	⁎*Staphylococcus aureus* colonization elevates IL-1β/IL-6. ⁎Roseomonas mucosa transplants reduce inflammation via TLR2 suppression.	Microbiota shifts (e.g., Faecalibaculum enrichment) worsen oxazolone-induced inflammation.	[52-54]
Stress Models	Social isolation in NC/Nga mice exacerbates scratching via substance P/NGF. Chronic stress amplifies IL-33/TSLP crosstalk.	Stress-independent (CD models focus on direct irritant/allergen exposure).	[68]
3D Skin Models	⁎Patient-derived RHE with Th2 cytokines (IL-4/IL-13/IL-22) mimics AD lesions. ⁎CRISPR-edited keratinocytes (e.g., FLG KO) replicate barrier defects.	⁎EpiDerm™ exposed to nickel or SLS shows disrupted tight junctions and IL-1β release. ⁎HaCaT monolayers with NLRP3 activation model irritant responses.	[54,55]
Immune Polarization	Th2/Th22 dominance (IL-4, IL-13, IL-22) with suppressed Th1/Th17.	Th1/Th17 dominance (IFN-γ, IL-17) in ACD; innate-driven (NLRP3) in irritant CD.	[56,57]
Key Limitations	Over-reliance on Th2 cytokines *In -vitro*; murine models lack human-like chronicity.	Murine models overemphasize Th1 responses vs. human ACD. Lack of sensory neuron integration in pruritus studies.	[60-65]
Recent Advances	⁎IL-31-targeting biologics (nemolizumab) and JAK inhibitors (delgocitinib). ⁎Microbiome-engineered models with *R. mucosa*.	⁎NLRP3 inhibitors (MCC950) and TRPV1 antagonists (PAC-14028). ⁎Low-dose tolerance models to study regulatory T-cell induction.	[64,65]
Readouts	⁎Serum IgE:Marked elevation. ⁎Scratching behavior: Chronic scratching (IL-33/TSLP-mediated), compulsive grooming,& stress-aggravated pruritus.	⁎Ear thickness: Measured via micrometer. ⁎Cytokineprofiling: IL-1β, TNF-α . Acute scratching (TRPV1-dependent), limb withdrawal (nociception),& alloknesis (itch from light touch).	[65-67]

11. CLINICAL TRIAL DATA & EFFICACY

11.1 In Atopic Dermatitis

Dupilumab (anti-IL-4Rα) Phase III trials showed ~50-60% of patients achieving EASI-75 (75% improvement on eczema area severity index). In head-to-head trials, JAK inhibitors (abrocitinib, upadacitinib) demonstrated faster itch relief and superior efficacy. Topical corticosteroids remain standard for flare control, but long-term use is limited by side effects[60-65].

11.2 In Contact Dermatitis

Clinical trials focus on topical corticosteroids for acute inflammation; Hydrocortisone & mometasone show good efficacy[57-59]. Patch testing and allergen avoidance are critical for long-term management. Limited data on systemic treatment exist.

12. CONCLUSION & FUTURE ASPECTS OF ATOPIC DERMATITIS (AD) VS. CONTACT DERMATITIS (CD)

12.1. Conclusion of Atopic Dermatitis (AD) Vs. Contact Dermatitis (CD)

Atopic Dermatitis (AD) and Contact Dermatitis (CD) have distinct pathophysiological mechanisms. AD is caused by Th2-skewed immune dysregulation, epidermal barrier defects, & microbiome imbalances. CD, particularly allergic contact dermatitis, involves Th1/Th17 polarization and hapten-specific T-cell activations. Traditional therapies like topical steroids and calcineurin inhibitors are foundational, while CD management relies on allergen avoidance and localized anti-inflammatory strategies[60,61].

12.2. Future Aspects of Atopic Dermatitis (AD) Vs. Contact Dermatitis (CD)

• Personalized medicine included in Atopic Dermatitis Biomarker-driven therapies targeting IL-31 and IL-18/IL-17 (ACD), alongside microbiome modulation through) probiotics or topical agents like (e.g., Lactobacillus) to ↓ *S. aureus* colonization[62].

• Novel therapeutics include IL-13/IL-31 inhibitors, JAK1/STAT6 inhibitors, and PDE4-targeted topicals[63].

• Coexistence management strategies include dual-diagnosis strategies and combination therapy [64].

• Herbal innovations include nanoparticle delivery systems and synergistic formulations[65].

•Probiotic treatment treats atopic disorders by modulating the gut-skin axis.

• Early-life probiotic supplementation and epigenetic modification that targets DNA methylation patterns linked to filaggrin are two prevention strategies [64,68].

Acknowledgement:

We are very thankful to the Department of Pharmacology, the Principal, and Management of C.L. Baid Metha College of Pharmacy for providing the facilities to conduct the research.

REFERENCES:

1. Cotsarelis G, Kaur P, Dhouailly D, Hengge U, Bickenbach J. Epithelial stem cells in the skin: definition, markers, localization and functions. Experimental dermatology. 1999 Feb;8(1):80-8.
2. Smith SM, Nedorost ST. "Dermatitis" defined. DERM. 2010 Oct 1;21(5):248-50.
3. Bieber T. How to define atopic dermatitis?. Dermatologic clinics. 2017 Jul 1;35(3):275-81.
4. Bieber T. Other types of dermatitis. InBraun-Falco's Dermatology 2009 (pp. 425-433). Springer, Berlin, Heidelberg.
5. Fonacier L, Bernstein DI, Pacheco K. Contact dermatitis: A practice parameter-update 2015. J Allergy Clin Immunol Pract. 2015;3(3 Suppl):S1-39.
6. Borda LJ, Wikramanayake TC. Seborrheic dermatitis and dandruff: a comprehensive review. J Clin Investig Dermatol. 2015;3(2):10.
7. Prignano F, Bonciani D, Bonciolini V, Lotti T. Lichen simplex chronicus: a clinical update. Dermatol Ther. 2012;25(5):458-62.
8. Jones, S., Tatnall, F., & Cunliffe, W. (1994). Perioral dermatitis: a review. Br J Dermatol, 130(2), 125–129.
9. Roberts WE. Skin type classification systems old and new. Dermatologic clinics. 2009 Oct 1;27(4):529-33.
10. Rawlings AV. Ethnic skin types: are there differences in skin structure and function? 1. International journal of cosmetic science. 2006 Apr;28(2):79-93.
11. Rubins A, Romanova A, Septe M, Maddukuri S, Schwartz RA, Rubins S. Contact dermatitis: etiologies of the allergic and irritant type. Acta Dermatovenerol Alp Pannonica Adriat. 2020 Dec 1;29(4):181-4.
12. Li Y, Li L. Contact dermatitis: classifications and management. Clinical reviews in allergy & immunology. 2021 Dec;61(3):245-81.
13. Contact dermatitis: symptoms, causes, types & treatments. (2024). Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/6173-contact-dermatitis.
14. Tokura, Y., & Hayano, S. (2022). Subtypes of Atopic Dermatitis: From Phenotype to Endotype. Allergol Int, 71(1), 14–24.
15. Lugović-Mihić L, Meštrović-Štefekov J, Potočnjak I, Cindrić T, Ilić I, Lovrić I, et al. Atopic dermatitis: Disease features, therapeutic options, and a multidisciplinary approach [Internet]. U.S. National Library of Medicine; 2023 [cited 2025 May 4]. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10305021/
16. Madison KC. Barrier function of the skin: "la raison d'être" of the epidermis. J Invest Dermatol. 2003;121(2):231-41.
17. Rubins A, Romanova A, Septe M, Maddukuri S, Schwartz RA, Rubins S. Contact dermatitis: etiologies of the allergic and irritant type. Acta Dermatovenerol Alp Pannonica Adriat. 2020 Dec 1;29(4):181-4.
18. Johansen JD, Hald M, Andersen BL, Laurberg G, Danielsen A, Avnstorp C, Kristensen B, Kristensen O, Kaaber K, Thormann J, Menné T. Classification of hand eczema: clinical and aetiological types. Based on the guideline of the Danish Contact Dermatitis Group. Contact Dermatitis. 2011 Jul;65(1):13-21.
19. Vocanson M, Hennino A, Cluzel-Tailhardat M, et al. Effector mechanisms in allergic contact dermatitis. Allergy.2009;64(12):1699-714.
20. Tokura Y, Hayano S. Subtypes of atopic dermatitis: From phenotype to endotype. Allergology International. 2022;71(1):14-24.
21. Peng W, Novak N. Pathogenesis of atopic dermatitis. Clinical & Experimental Allergy. 2015 Mar;45(3):566-74.
22. Rustemeyer T, Van Hoogstraten IM, Von Blomberg BM, Scheper RJ. Mechanisms of allergic contact dermatitis. Kanerva's occupational dermatology. 2020:151-90.
23. Leung DY, Boguniewicz M, Howell MD, et al. New insights into atopic dermatitis. J Clin Invest. 2004;113(5):651-7.
24. Owen JL, Vakharia PP, Silverberg JI. The role and diagnosis of allergic contact dermatitis in patients with atopic dermatitis [Internet]. U.S. National Library of Medicine; 2018 [cited 2025 May 4]. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC5948135/
25. H. Alenius, D. Laouini, A. Woodward, E. Mizoguchi, A.K. Bhan, E. Castigli, et al.Mast cells regulate IFN-gamma expression in the skin and circulating IgE levels in allergen-induced skin inflammation J Allergy Clin Immunol, 109 (2002), pp. 106-113.
26. Lipozencic J, Wolf R. Nummular dermatitis. Clin Dermatol. 2010;28(2):151-9.
27. Hafner J, Schneider E, Burg G. Stasis dermatitis. Dermatology. 1997;194(2):94-8.

28. Salameh F, Perla D, Solomon M, Gamus D, Barzilai A, Greenberger S, Trau H. The effectiveness of combined Chinese herbal medicine and acupuncture in the treatment of atopic dermatitis. The Journal of Alternative and Complementary Medicine. 2008 Oct 1;14(8):1043-8.
29. Liu J, Mo X, Wu D, Ou A, Xue S, Liu C, Li H, Wen Z, Chen D. Efficacy of a Chinese herbal medicine for the treatment of atopic dermatitis: a randomised controlled study. Complementary Therapies in Medicine. 2015 Oct 1;23(5):644-51.
30. Rietschel RL, Fowler JF Jr. Fisher's Contact Dermatitis. Hamilton: BC Decker; 2008.
31. Elmets CA, Maibach HI. Photosensitive contact dermatitis. Arch Dermatol. 1980;116(1):15-20.
32. Kanerva L. Protein contact dermatitis: diagnosis. Br J Dermatol. 2000;142(2):21922.
33. De Vuyst E, Salmon M, Evrard C, Lambert de Rouvroit C, Poumay Y. Atopic dermatitis studies through in vitro models. Frontiers in Medicine. 2017 Jul 24;4:119.
34. Smith CH, Anstey AV. Misuse of topical corticosteroids: A clinical study. Br J Dermatol . 2002 [cited 2024 Apr 30];146(6):943-9.
35. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al.Common loss-of-function variants of the epidermal barrier protein filaggrin. Nat Genet.2006;38(4):441-6.
36. Namazi MR. Green tea induces Th1 cytokine profile. Med Hypotheses 2004;62(3):482-5.
37. Tokura Y, Hayano S. Subtypes of Atopic Dermatitis: From Phenotype to Endotype. Allergol Int. 2022;71(1):14-24.
38. Lee J, Kim YS. Turmeric (Curcuma longa) suppresses allergic contact dermatitis in mice. Food Chem Toxicol. 2012;50(8):2681-9.
39. JI; OJP. The role and diagnosis of allergic contact dermatitis in patients with atopic dermatitis [Internet]. U.S. National Library of Medicine; [cited 2025 May 4]. Available from: https://pubmed.ncbi.nlm.nih.gov/29305764/
40. Man MQ, Hatano Y, et al. Effects of house dust mite allergens on murine skin. J Invest Dermatol.2001;116(5):843-9.
41. Ashcroft DM, Po AL, Williams HC, et al. Systematic review of topical corticosteroid use in atopic dermatitis. Br J Dermatol. 2000;142(5):933-44.
42. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 Trials of Dupilumab in Atopic Dermatitis. N Engl J Med. 2016;375(24):2335-48.
43. Loden M. Topical corticosteroids and calcineurin inhibitors in AD. Dermatol Ther. 2017;7(4):453-46.
44. Dureja H, Kaushik D, et al. Developments in topical drug delivery systems. Indian J Pharm Sci. 2005;67(3):238.
45. Proksch E, Brandner JM, Jensen JM. The skin: an indispensable barrier.Exp Dermatol. 2008;17(12):1063-72.
46. Vocanson M, Hennino A, Cluzel-Tailhardat M, et al. Effector mechanisms in allergic contact dermatitis. Allergy.2009;64(12):1699-714.
47. Leung DY, Boguniewicz M, Howell MD, et al. New insights into atopic dermatitis. J Clin Invest. 2004;113(5):651-7.
48. D. Barton, H. HogenEsch, F. WeihMice lacking the transcription factor RelB develop T cell-dependent skin lesions similar to human atopic dermatitis Eur J Immunol, 30 (2000), pp. 2323-2332.
49. Tramontana M, Hansel K, Bianchi L, Sensini C, Malatesta N, Stingeni L. Advancing the understanding of allergic contact dermatitis: From pathophysiology to novel therapeutic approaches [Internet]. U.S. National Library of Medicine;2023[cited2025May4].Availablefrom:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239928/
50. Usatine RP, Riojas M. Diagnosis and management of contact dermatitis. Am Fam Physician. 2010 Aug 1;82(3):249-55.
51. Flower RJ, Rothwell NJ. Lipocortin-1: Cellular mechanisms and clinical relevance. Trends Pharmacol Sci [Internet]. 1994 [cited 2024 Apr 30);15(3):71-6. Available from: https://doi.org/10.1016/0165-6147(94)90105-8 (Example for molecular action).
52. Smith CH, Anstey AV. Misuse of topical corticosteroids: A clinical study. Br J Dermatol [Internet]. 2002 [cited 2024 Apr 30];146(6):943-9. Available from: https://doi.org/10.1046/j.1365-2133.2002.04785.x
53. Liu J, Mo X, Wu D, Ou A, Xue S, Liu C, Li H, Wen Z, Chen D. Efficacy of a Chinese herbal medicine for the treatment of atopic dermatitis: a randomised controlled study. Complementary Therapies in Medicine. 2015 Oct 1;23(5):644-51.
54. Jin H, He R, Oyoshi M, Geha RS. Animal models of atopic dermatitis. J Invest Dermatol. 2009 Jan;129(1):31-40. doi: 10.1038/jid.2008.106. PMID: 19078986; PMCID: PMC2886143.
55. Kaur I, et al. Meta-analysis of herbal treatments in atopic dermatitis. Phytother Res. 2020;34(12):3166-3177.
56. L.S. Chan, N. Robinson, L. XuExpression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitisJ Invest Dermatol, 117 (2001), pp. 977-983.
57. Y. Chen, C.L. Langrish, B. McKenzie, B. JoyceShaikh, J.S. Stumhofer, T. McClanahan, et al Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis.
58. Holmdahl M, Ahlfors SR, Holmdahl R et al (2008) Structure-immune response relationships of hapten-modified collagen II peptides in a T-cell model of allergic contact dermatitis. Chem Res Toxicol 21(8):1514–1523.
59. Christensen AD, Haase C (2012) Immunological mechanisms of contact hypersensitivity in mice. APMIS 120(1):1–27.
60. Gaide O, Emerson RO, Jiang X et al (2015) Common clonal origin of central and resident memory T cells following skin immunization. Nat Med 21(6):647–653.
61. Martin SF, Esser PR, Weber FC et al (2011) Mechanisms of chemical-induced innate immunity in allergic contact dermatitis. Allergy 66(9):1152–1163 .

62. Dudeck A, Dudeck J, Scholten J et al (2011) Mast cells are key promoters of contact allergy that mediate the adjuvant effects of haptens. Immunity 34(6):973–984.
63. Chopra R; Vakharia PP;Sacotte R;Patel N;Immaneni S;White T;Kantor R;Hsu DY;Silverberg JI; Severity strata for eczema area and severity index (EASI), modified EASI, scoring atopic dermatitis (SCORAD), objective SCORAD, atopic dermatitis severity index and body surface area in adolescents and adults with atopic dermatitis [Internet]. U.S. National Library of Medicine; [cited 2025 May 4]. Available from:https://pubmed.ncbi.nlm.nih.gov/28485036/
64. Zollner TM, Igney FH, Asadullah K. Acute and chronic models of allergic contact dermatitis: advantages and limitations. Animal models of T cell-mediated skin diseases. 2005 Jan 1:255-75.
65. Löwa A, Jevtić M, Gorreja F, Hedtrich S. Alternatives to animal testing in basic and preclinical research of atopic dermatitis. Experimental dermatology. 2018 May;27(5):476-83.
66. Wollenberg A, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two phase 3 trials. J Allergy Clin Immunol. 2021;147(4):1344-1355.
67. Silverberg JI, et al. Upadacitinib for atopic dermatitis: phase 3 trials. J Am Acad Dermatol. 2021;85(4):863-872.
A. Aioi, H. Tonogaito, H. Suto, K. Hamada, C.R. Ra, H. Ogawa, et al.Impairment of skin barrier function in NC/Nga Tnd mice as a possible model for atopic dermatitis Br J Dermatol, 144 (2001), pp.12.

How to cite this article:
Archana P et al. Ijppr.Human, 2025; Vol. 31 (5): 186-196.
Conflict of Interest Statement: All authors have nothing else to disclose.